Key result
Therapeutic propranolol fails to alter platelet function in healthy young subjects.
Why the study?
The effects of therapeutic doses of propranolol on platelet function in healthy subjects were unclear.
Does oral propranolol affect platelet function in healthy young subjects?
Does oral propranolol affect platelet function in healthy young subjects?
Therapeutic doses of oral propranolol do not significantly alter platelet function in healthy subjects.
Does not alter platelet monitoring for propranolol in healthy subjects; leaves open effects in cardiovascular disease populations.
Propranolol, a non-selective beta blocker, was administered orally in therapeutic doses. The effects of a single dose (160 mg) and one week's treatment (80 mg twice a day) on platelet function were compared in healthy young subjects. There were no significant changes in circulating platelet aggregates, template bleeding time, platelet factor 3 availability and thromboxane beta 2 (TX beta 2) generation. Platelet aggregation responses as assessed by angle of slope and maximal percentage aggregation (all agonists) and lag phase (collagen) showed no changes of biological importance, although minor changes reaching significance were observed with some agonists. These findings suggest that propranolol does not significantly affect platelet function when taken at doses commonly encountered in clinical practice.
No takes yet. Share an insight, caveat, or question.
Pamphilon et al. (1989) studied Healthy. Propranolol was evaluated on Platelet function (circulating platelet aggregates, template bleeding time, platelet factor 3 availability, and TX beta 2 generation). Propranolol administered at therapeutic doses did not significantly affect measurable platelet function in healthy young subjects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: